{"a":[{"_":" What did we learn from Big Pharma’s Q2 results?","$":{"href":"/pharma/what-did-we-learn-big-pharmas-q2-results","hreflang":"en"}}]}

EarningsGLP-1 oral agentsNeutral

AI Analysis

Summary

Fierce Pharma editors provide an analysis of Big Pharma's second-quarter results, covering topics including AI developments, leadership changes, the oral GLP-1 competitive landscape, and emerging blockbuster candidates.

Importance:4/10

Sentiment:

0.00

earningsQ2 resultsBig PharmaGLP-1AIleadershipblockbusters

Read the original article

Published by FiercePharma on August 18, 2026 12:34 PM

Read Original

{"a":[{"_":" What did we learn from Big Pharma’s Q2 results?","$":{"href":"/pharma/what-did-we-learn-big-pharmas-q2-results","hreflang":"en"}}]}

Summary

{"a":[{"_":" What did we learn from Big Pharma’s Q2 results?","$":{"href":"/pharma/what-did-we-learn-big-pharmas-q2-results","hreflang":"en"}}]}